United Therapeutics' Ralinepag Shows Potential in Improving Exercise Capacity in PH Patients
The ADVANCE CAPACITY study evaluates ralinepag's impact on exercise capacity in patients with WHO Group 1 pulmonary hypertension.
Asset / Drug
Drug and asset intelligence for Ralinepag with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.